For close to 50 years, a type of immunotherapy called Bacillus Calmette–Guerin (BCG) therapy has been used to treat early-stage bladder cancer.It’s still the regimen of choice, but a new study has indicated that combining BCG with a chemotherapy drug might be better for some.It could also go some way to addressing a global shortage of BCG, because it requires fewer doses of the immunotherapy.Guest/sProfessor Dickon Hayne, head of urology at Fiona Stanley Hospital in Perth and leader of urological research at the University of Western AustraliaReferencesMitomycin + BCG as Adjuvant Intravesical Therapy for High-Risk Non–muscle-Invasive Bladder Cancer: A Randomized Phase 3 Trial

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related